For many biopharma leaders in the U.S. today, the question isn't whether direct-to-patient (DTP) can drive impact – it's whether it can truly move the needle for their patients. Invest too broadly and returns can disappoint; wait too long and the moment to shape demand may pass.
That's where our DTP readiness assessment comes in; a fact-based framework that distills complex market and patient dynamics into a clear readiness signal. By assessing your product across therapeutic area, access, digital adoption, and patient behavior, it helps you understand if, where, and how DTP can create value.
At Herspiegel, we help clients make confident, data-driven decisions in an evolving market. This tool is one of the ways we bring clarity to complex choices.
Start the assessment and see where DTP could take your product.